The biotechnology sector is currently at a strategic crossroads, facing major structural and technological challenges. The "patent cliff" continues to pose a significant threat to industry revenues, with a potential loss estimated at $400 billion. Concurrently, integrating artificial intelligence (AI) into research and development (R&D) processes is emerging as a crucial solution to maintain competitiveness. Recent initiatives, such as Bristol Myers Squibb's acquisition of the Nvidia DGX SuperPOD system, illustrate the transformative potential of these technologies. However, they also raise security and ethical questions, particularly concerning intellectual property and cyber risks.